“…10,49,[53][54][55][56] In these patient populations, ESAs have been shown to increase Hb levels, reduce allogeneic transfusion, increase aerobic capacity, and improve quality of life. 57 The ability of ESAs to reduce transfusions has been balanced by recent concerns of increased adverse outcomes (thrombosis, cancer progression) associated with ESA therapy in patients undergoing spine surgery and in patients with chronic renal failure and Sources: O'Brien et al 44 Vamvakas et al 43 RBC = red blood cells; HIV = human immunodeficiency virus; HCV = hepatitis C virus; HBV = hepatitis B virus; HTLV = Human T-cell leukemia/lymphoma virus; WNV = West Nile virus cancer.…”